Detailed in the journal Nature Microbiology, the discovery unveils a promising new treatment option for millions of people affected by Crohn’s disease and other related conditions, while also showcasing important new applications for AI in drug discovery research.

“This work shows that we’re still just scratching the surface as far as AI-guided drug discovery goes,” says Jon Stokes, an assistant professor in McMaster’s Department of Biochemistry and Biomedical Sciences and principal investigator on the new study.

“The development of our new drug, which is designed to target IBD, has been fast-tracked thanks to the collaboration between humans and generative AI.”